末梢動脈疾患治療薬市場：治療タイプ、適応ステージ、エンドユーザー別-2025-2030年の世界予測

末梢動脈疾患治療薬市場は、2023年に47億5,000万米ドルと評価され、2024年には51億4,000万米ドルに達すると予測され、CAGR 8.73％で成長し、2030年には85億5,000万米ドルに達すると予測されています。

末梢動脈疾患（PAD）治療薬市場の範囲と定義には、PADの診断、治療、管理が含まれます。PADは、動脈の狭窄によって手足の血流が減少することを特徴とする疾患です。効果的なPAD治療薬の必要性は、糖尿病、高血圧、肥満などの危険因子の有病率の増加から生じています。応用分野には医薬品（抗血小板薬、スタチンなど）、医療機器（ステント、血管形成バルーン）、患者の転帰改善を目的とした生活習慣管理プログラムなどがあります。最終用途分野には、主に病院、専門クリニック、在宅医療環境が含まれます。市場の洞察によると、成長を促進する主な要因としては、低侵襲治療の進歩、PADに対する意識の高まり、血管障害を起こしやすい老人人口の急増などが挙げられます。最近のビジネスチャンスとしては、薬剤溶出技術や生物製剤の開発、医療介入と患者のデジタルモニタリングの両方を提供する統合ヘルスケアソリューションなどが挙げられます。こうした機会を活用するため、企業は個別化医療への研究開発投資やデジタルヘルス・ソリューションのためのハイテク企業との提携に注力すべきです。有望な成長にもかかわらず、市場は先進治療の高コスト、規制上のハードル、患者の治療レジメン遵守の課題といった限界に直面しています。さらに、新興地域ではヘルスケアへのアクセスが限られており、総合的な診断施設が不足していることも市場の成長を制約しています。革新的な研究分野には、遺伝子治療の探求、動脈修復のための再生医療、PADの早期発見と管理のためのAI技術の開発などがあります。市場の性質はダイナミックで、技術の進歩やヘルスケア政策の変化に大きく影響されます。持続的な事業成長を確保するため、企業は治療イノベーションと患者中心のケアモデルを組み合わせた適応可能な戦略を優先し、十分なサービスを受けていない地域でのアクセス拡大のための潜在的な協力関係を検討すべきです。

市場力学：急速に進化する末梢動脈疾患治療薬市場の主要市場インサイトを公開

末梢動脈疾患治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢者人口の増加に伴う末梢動脈疾患の罹患率の上昇
  • 世界の不健康なライフスタイルへのシフトの増加
  • 低侵襲血管内治療への嗜好の高まり
• 市場抑制要因
  • 末梢動脈疾患の治療に伴う高コスト
• 市場機会
  • 末梢動脈疾患の先進治療の研究開発
  • 末梢動脈疾患治療のための製品承認の増加
• 市場の課題
  • 末梢動脈疾患機器に熟練した専門家や医師の不足

ポーターの5つの力：末梢動脈疾患治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：末梢動脈疾患治療薬市場における外部からの影響の把握

外部マクロ環境要因は、末梢動脈疾患治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析末梢動脈疾患治療薬市場における競合情勢の把握

末梢動脈疾患治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス末梢動脈疾患治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、末梢動脈疾患治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨末梢動脈疾患治療薬市場における成功への道筋を描く

末梢動脈疾患治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化人口の増加に伴い末梢動脈疾患の発生率が上昇
    • 世界中で不健康なライフスタイルへの移行が増加
    • 低侵襲血管内手術への関心が高まる
  • 抑制要因
    • 末梢動脈疾患の治療に伴う高額な費用
  • 機会
    • 末梢動脈疾患の先進的治療法の研究開発
    • 末梢動脈疾患の治療薬承認が増加
  • 課題
    • 末梢動脈疾患の機器に精通した熟練した専門家や医師の不足
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 末梢動脈疾患治療薬市場治療の種類別

• 医薬品
  • 降圧剤
  • ナフチドロフリルシュウ酸塩
  • スタチン
• 外科的治療
  • 血管形成術
  • 動脈バイパス移植

第7章 末梢動脈疾患治療薬市場適応症ステージ別

• 無症状
• 虚血性安静時疼痛
• 軽度の跛行
• 中等度/重度の跛行
• 潰瘍/壊疽

第8章 末梢動脈疾患治療薬市場：エンドユーザー別

• 病院
• 専門クリニック

第9章 南北アメリカの末梢動脈疾患治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の末梢動脈疾患治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの末梢動脈疾患治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alucent Biomedical Inc.
• AnGes, Inc.
• AngioDynamics, Inc.
• ARCA biopharma, Inc.
• B. Braun SE
• Becton, Dickinson and Company
• BIOTRONIK SE & Co. KG
• Boston Scientific Corporation
• Cook Group Incorporated
• Helixmith Co., Ltd.
• Koninklijke Philips N.V.
• LeMaitre Vascular, Inc.
• Medtronic PLC
• Meril Life Sciences Pvt. Ltd.
• MicroPort Scientific Corporation
• REVA Medical, LLC
• Terumo Corporation
• Venturis Therapeutics, Inc.
• W. L. Gore & Associates, Inc.

LIST OF FIGURES

• FIGURE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERTENSIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY NAFTIDROFURYL OXALATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ANGIOPLASTY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ARTERY BYPASS GRAFT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ASYMPTOMATIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ISCHEMIC REST PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MILD CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MODERATE/SEVERE CLAUDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY ULCERS/GANGRENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 42. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 43. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 46. CANADA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 69. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 73. CHINA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 74. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 78. INDIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 160. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 164. ITALY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 180. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 184. POLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 185. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 186. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 189. QATAR PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY INDICATION STAGE, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
• TABLE 235. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 236. PERIPHERAL ARTERIAL DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Peripheral Arterial Disease Therapeutics Market was valued at USD 4.75 billion in 2023, expected to reach USD 5.14 billion in 2024, and is projected to grow at a CAGR of 8.73%, to USD 8.55 billion by 2030.

The scope and definition of the Peripheral Arterial Disease (PAD) therapeutics market encompass the diagnosis, treatment, and management of PAD, a condition characterized by narrowed arteries reducing blood flow to the limbs. The necessity for effective PAD therapeutics arises from the increasing prevalence of risk factors like diabetes, hypertension, and obesity. Application areas include pharmaceuticals (e.g., anti-platelet drugs, statins), medical devices (stents, angioplasty balloons), and lifestyle management programs aimed at improving patient outcomes. End-use sectors primarily involve hospitals, specialty clinics, and home care settings. Market insights reveal that key factors driving growth include advancements in minimally invasive treatments, increasing awareness about PAD, and a surge in the geriatric population prone to vascular disorders. Recent opportunities are present in the development of drug-eluting technologies and biologics, as well as integrated healthcare solutions offering both medical intervention and digital monitoring of patients. To capitalize on these opportunities, companies should focus on R&D investments in personalized medicine and partnerships with tech firms for digital health solutions. Despite the promising growth, the market faces limitations such as high costs of advanced therapies, regulatory hurdles, and challenges in patient adherence to treatment regimens. Moreover, the market's growth is constrained by limited access to healthcare in emerging regions and a lack of comprehensive diagnostic facilities. Innovative research areas include the exploration of gene therapy, regenerative medicine for arterial repair, and the development of AI technologies for early PAD detection and management. The market nature is dynamic, heavily influenced by technological advancements and changing healthcare policies. To ensure sustained business growth, companies should prioritize adaptable strategies that couple treatment innovation with patient-centric care models and consider potential collaborations for expanding access in underserved regions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peripheral Arterial Disease Therapeutics Market

The Peripheral Arterial Disease Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidences of peripheral arterial disease with an increasing geriatric population
  • Increasing shift toward unhealthy lifestyles among people globally
  • Growing preference for minimally invasive endovascular procedures
• Market Restraints
  • High cost associated with treatment of peripheral arterial disease
• Market Opportunities
  • Research and development for advanced treatments for peripheral arterial disease
  • Growing product approvals for the treatment of peripheral arterial disease
• Market Challenges
  • Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices

Porter's Five Forces: A Strategic Tool for Navigating the Peripheral Arterial Disease Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peripheral Arterial Disease Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peripheral Arterial Disease Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peripheral Arterial Disease Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peripheral Arterial Disease Therapeutics Market

A detailed market share analysis in the Peripheral Arterial Disease Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peripheral Arterial Disease Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peripheral Arterial Disease Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Peripheral Arterial Disease Therapeutics Market

A strategic analysis of the Peripheral Arterial Disease Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Peripheral Arterial Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alucent Biomedical Inc., AnGes, Inc., AngioDynamics, Inc., ARCA biopharma, Inc., B. Braun SE, Becton, Dickinson and Company, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Cook Group Incorporated, Helixmith Co., Ltd., Koninklijke Philips N.V., LeMaitre Vascular, Inc., Medtronic PLC, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, REVA Medical, LLC, Terumo Corporation, Venturis Therapeutics, Inc., and W. L. Gore & Associates, Inc..

Market Segmentation & Coverage

This research report categorizes the Peripheral Arterial Disease Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Treatment Type, market is studied across Medications and Surgical Treatments. The Medications is further studied across Antihypertensives, Naftidrofuryl Oxalate, and Statins. The Surgical Treatments is further studied across Angioplasty and Artery Bypass Graft.
• Based on Indication Stage, market is studied across Asymptomatic, Ischemic Rest Pain, Mild Claudication, Moderate/Severe Claudication, and Ulcers/Gangrene.
• Based on End-Users, market is studied across Hospitals and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidences of peripheral arterial disease with an increasing geriatric population
    • 5.1.1.2. Increasing shift toward unhealthy lifestyles among people globally
    • 5.1.1.3. Growing preference for minimally invasive endovascular procedures
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with treatment of peripheral arterial disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Research and development for advanced treatments for peripheral arterial disease
    • 5.1.3.2. Growing product approvals for the treatment of peripheral arterial disease
  • 5.1.4. Challenges
    • 5.1.4.1. Lack of skilled professionals and doctors with proficiency in peripheral arterial disease devices
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Peripheral Arterial Disease Therapeutics Market, by Treatment Type

• 6.1. Introduction
• 6.2. Medications
  • 6.2.1. Antihypertensives
  • 6.2.2. Naftidrofuryl Oxalate
  • 6.2.3. Statins
• 6.3. Surgical Treatments
  • 6.3.1. Angioplasty
  • 6.3.2. Artery Bypass Graft

7. Peripheral Arterial Disease Therapeutics Market, by Indication Stage

• 7.1. Introduction
• 7.2. Asymptomatic
• 7.3. Ischemic Rest Pain
• 7.4. Mild Claudication
• 7.5. Moderate/Severe Claudication
• 7.6. Ulcers/Gangrene

8. Peripheral Arterial Disease Therapeutics Market, by End-Users

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Specialty Clinics

9. Americas Peripheral Arterial Disease Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Peripheral Arterial Disease Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Peripheral Arterial Disease Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alucent Biomedical Inc.
• 3. AnGes, Inc.
• 4. AngioDynamics, Inc.
• 5. ARCA biopharma, Inc.
• 6. B. Braun SE
• 7. Becton, Dickinson and Company
• 8. BIOTRONIK SE & Co. KG
• 9. Boston Scientific Corporation
• 10. Cook Group Incorporated
• 11. Helixmith Co., Ltd.
• 12. Koninklijke Philips N.V.
• 13. LeMaitre Vascular, Inc.
• 14. Medtronic PLC
• 15. Meril Life Sciences Pvt. Ltd.
• 16. MicroPort Scientific Corporation
• 17. REVA Medical, LLC
• 18. Terumo Corporation
• 19. Venturis Therapeutics, Inc.
• 20. W. L. Gore & Associates, Inc.